Imprimis Pharmaceuticals (IMMY) Receiving Somewhat Favorable News Coverage, Analysis Finds
News stories about Imprimis Pharmaceuticals (NASDAQ:IMMY) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Imprimis Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.6154744412128 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Imprimis Pharmaceuticals (IMMY) traded up 2.22% during mid-day trading on Friday, hitting $2.30. 178,067 shares of the stock were exchanged. The stock’s market capitalization is $46.15 million. The stock’s 50-day moving average is $2.67 and its 200-day moving average is $3.11. Imprimis Pharmaceuticals has a 52 week low of $1.65 and a 52 week high of $4.69.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last issued its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.29. Imprimis Pharmaceuticals had a negative net margin of 57.07% and a negative return on equity of 242.66%. The company had revenue of $6.86 million during the quarter. Analysts forecast that Imprimis Pharmaceuticals will post ($0.86) earnings per share for the current fiscal year.
IMMY has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. ValuEngine lowered shares of Imprimis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 16th.
In other news, Director Robert J. Kammer sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $3.05, for a total value of $30,500.00. Following the completion of the sale, the director now directly owns 1,059,827 shares in the company, valued at approximately $3,232,472.35. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 12.55% of the company’s stock.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.